Indacaterol/mometasone furoate combination: synergism in human hyperresponsive airway smooth muscle

L. Calzetta (Rome, Italy), B. Ritondo (Rome, Italy), I. Nikolaev (Basel, Switzerland), M. Cazzola (Rome, Italy), M. Matera (Naples, Italy), P. Rogliani (Rome, Italy)

Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma
Session: Clinical and laboratory pharmacology in asthma
Session type: E-poster session
Number: 1416
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
L. Calzetta (Rome, Italy), B. Ritondo (Rome, Italy), I. Nikolaev (Basel, Switzerland), M. Cazzola (Rome, Italy), M. Matera (Naples, Italy), P. Rogliani (Rome, Italy). Indacaterol/mometasone furoate combination: synergism in human hyperresponsive airway smooth muscle. 1416

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A comparison of beta2-adrenoceptor desensitisation induced by olodaterol and formoterol in human lung mast cells and airway smooth muscle cells
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013

Inhaled budesonide induces corticosteroid-dependent gene expression in asthmatics: Validation in primary epithelial and airways smooth muscle cells
Source: Annual Congress 2011 - Models of disease and drug actions
Year: 2011


Effects of fluticasone and salmeterol on cytokine-induced airway smooth muscle IP10 release
Source: Eur Respir J 2005; 26: Suppl. 49, 712s
Year: 2005

The long-acting β2-agonist formoterol re-establishes the anti-proliferative effect of glucocorticoids in asthmatic airway smooth muscle cells (ASMC)
Source: Annual Congress 2011 - Understanding disease and drug mechanisms
Year: 2011



Proliferation is not increased in airway myofibroblasts isolated from asthmatics
Source: Eur Respir J 2008; 32: 362-371
Year: 2008



Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison
Source: Eur Respir J 2007; 30: 653-661
Year: 2007



Inhibition of IL-8 and RANTES release from cultured human airway smooth muscle cells by fluticasone and budesonide
Source: Eur Respir J 2002; 20: Suppl. 38, 384s
Year: 2002

Budesonide prevents cytokine-induced decrease of the relaxant response to formoterol but not to salmeterol in mouse trachea
Source: Annual Congress 2009 - Translational research/biomarkers
Year: 2009


Endothelin-1-mediated contraction of mouse small airways is resistant to salbutamol, but sensitive to rosiglitazone
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013

Mechanisms of bronchial hyperresponsiveness in a clinical setting – putative role of smooth muscle
Source: Annual Congress 2005 - Role of the bronchial smooth muscle in regulating airway disease
Year: 2005

Treating asthma means treating airway smooth muscle cells
Source: Eur Respir J 2008; 32: 265-274
Year: 2008



Beta2-agonists but not glucocorticoids inhibit proliferation of asthmatic airway smooth muscle cells
Source: Eur Respir J 2004; 24: Suppl. 48, 251s
Year: 2004

Impaired inhibitory action of corticosteroids on chemokine expression induced by TNFalpha in airway smooth muscle (ASM) cells from patients with severe asthma
Source: Annual Congress 2013 –Airway smooth muscle and cell biology
Year: 2013

IL-13 induces glucocorticoid-insensitive hyperreactivity of human small airways
Source: International Congress 2015 – Modulating the immune system in COPD and asthma
Year: 2015

Long-term effects of bronchial thermoplasty on airway smooth muscle and collagen deposition in severe asthma
Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives
Year: 2016

The anti-proliferative effect of hydrogen sulfide upon human airway smooth muscle in COPD
Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis
Year: 2014


Effect of nilotinib on airway smooth muscle thickening in a murine model of chronic asthma
Source: Annual Congress 2012 - New drug targets and pre-clinical models for respiratory diseases
Year: 2012


Fevipiprant reduces airway smooth muscle mass in asthmatics via PGD2 receptor antagonism
Source: International Congress 2017 – Novel mechanisms and treatments for asthma
Year: 2017




Involvement of the BK channels/G proteins processes in the synergistic effects between anticholinergic agents and beta2-adrenoceptor agonists in airway smooth muscle
Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management
Year: 2013


Inhaled roflumilast and tadalafil supress airway reactivity and inflammation in ovalbumin-sensitized guinea pigs
Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Year: 2016